- Celltrion and Hospira (HSP) get final approval from the European Commission for Inflectra.
- The rheumatoid arthritis treatment is a biosimilar of Johnson & Johnson (JNJ) and Merck's (MRK) Remicade ($2B in European sales last year).
- The news marks a biotech milestone: It's Europe's first biosimilar monoclonal antibody therapy.
- HSP will launch the drug "at the earliest opportunity taking into account any relevant patent protection." (PR)
Hospira's Inflectra becomes Europe's first approved biosimilar monoclonal antibody
Sep 10 2013, 08:49 ET